Aspirin for Primary Prevention: What the Evidence Actually Says in 2025

What Is Primary Prevention and Why Does the Aspirin Question Matter?

Primary prevention means reducing the risk of a first cardiovascular event in someone who has not yet had a heart attack, stroke, or confirmed coronary artery disease. For decades, physicians recommended low-dose aspirin (81 mg daily) to nearly all middle-aged adults for this purpose. That practice has shifted dramatically.

Three large randomized trials published between 2018 and 2019 changed the calculus. ASPREE, ARRIVE, and ASCEND enrolled a combined total of over 47,000 participants and each found that aspirin's benefit in primary prevention populations was smaller than previously assumed, while its bleeding risk was consistent and real. The USPSTF incorporated this evidence into its 2022 final recommendation statement, concluding that adults aged 40 to 59 with a 10-year CVD risk of 10% or greater should make an individual decision with their clinician (Grade C), and adults 60 and older should not start aspirin for primary prevention (Grade D). [1]

The distinction between primary and secondary prevention is sharp. If you have already had a heart attack or have documented atherosclerotic cardiovascular disease (ASCVD), aspirin remains a standard of care in most guidelines. This article covers only the primary prevention question.

What the Major Trials Actually Found

The three key trials each targeted a distinct population, and their results tell a consistent story.

ASPREE (Aspirin in Reducing Events in the Elderly) enrolled 19,114 community-dwelling adults aged 70 or older (65 and older for Black and Hispanic Americans) who were free of CVD, dementia, and physical disability. Median follow-up was 4.7 years. Aspirin 100 mg daily did not reduce the primary composite endpoint of disability-free survival (HR 1.01 to 95% CI 0.92-1.11, P<0.001 for non-inferiority was not met in the harm direction). Major hemorrhage occurred in 3.8% of the aspirin group versus 2.8% of the placebo group (HR 1.38 to 95% CI 1.18-1.62). The all-cause mortality finding, HR 1.14 (95% CI 1.01-1.29), was driven partly by a higher rate of cancer-related deaths, a signal that remains biologically unexplained and is under continued investigation. [2]

ARRIVE enrolled 12,546 adults at moderate cardiovascular risk (estimated 10-year risk approximately 17.3% in men, 9.7% in women). Over a median 60 months, the primary MACE endpoint was not significantly reduced: HR 0.96 (95% CI 0.81-1.13). Gastrointestinal bleeding occurred in 0.97% of the aspirin group versus 0.46% of the placebo group. [3]

ASCEND enrolled 15,480 adults with diabetes but no established CVD. Aspirin 100 mg daily reduced serious vascular events by 1.1 percentage points over 7.4 years (8.5% vs. 9.6%, RR 0.88 to 95% CI 0.79-0.97), but major bleeding rose by a nearly identical absolute margin (4.1% vs. 3.2%, RR 1.29 to 95% CI 1.09-1.52), largely canceling the net benefit. [4]

Taken together, these numbers show that the absolute risk reduction from aspirin in primary prevention populations is small, typically 0.5 to 1.0 percentage points over five or more years, while the absolute bleeding risk runs in the same range.

Who Might Still Benefit: The Narrow 40-59 Window

A small, well-defined group may still see net benefit from aspirin initiation. The USPSTF Grade C recommendation applies to adults aged 40 to 59 who have a calculated 10-year ASCVD risk of 10% or above. "The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one," the USPSTF 2022 statement reads. "Persons who are not at increased risk for bleeding and who have a higher CVD risk are more likely to benefit." [1]

Calculating that 10-year risk accurately matters. The ACC/AHA Pooled Cohort Equations incorporate age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure treatment status, diabetes status, and smoking status. [5] A 52-year-old male smoker with poorly controlled hypertension and LDL of 145 mg/dL may clear the 10% threshold where a 45-year-old non-smoking woman with optimal lipids almost certainly will not.

Factors that raise bleeding risk and should push the calculus away from aspirin include prior peptic ulcer disease, active GERD requiring proton pump inhibitors, concurrent NSAID use, anticoagulant therapy, thrombocytopenia, and chronic kidney disease (eGFR <30 mL/min/1.73m2). [6]

Why Aspirin Alone Was Never Enough: The Role of Statins

Aspirin addresses platelet aggregation. Statins address the underlying atherosclerotic process. For primary prevention, statins carry a far more favorable benefit-harm ratio than aspirin in most eligible populations, and the two are not interchangeable.

The JUPITER trial (N=17,802) randomized patients with LDL <130 mg/dL but elevated high-sensitivity CRP (hsCRP >2 mg/L) to rosuvastatin 20 mg (Crestor) or placebo. The trial was stopped early after a median 1.9 years because rosuvastatin reduced the primary MACE endpoint by 44% (HR 0.56 to 95% CI 0.46-0.69, P<0.001). Absolute risk reduction was 0.59 events per 100 person-years. [7] That magnitude of benefit substantially exceeds what aspirin achieves in comparable populations.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease places statins at the center of pharmacologic primary prevention, recommending initiation in adults aged 40 to 75 with LDL 70-189 mg/dL and a 10-year ASCVD risk of 7.5% or higher after a clinician-patient risk discussion. [8] Aspirin gets a much more cautious endorsement in the same document.

Statin Options for Primary Prevention: Atorvastatin, Rosuvastatin, Simvastatin, and Ezetimibe

Choosing among available lipid-lowering agents depends on required LDL reduction, drug interactions, patient tolerability, cost, and whether combination therapy is needed.

Atorvastatin (Lipitor)

Atorvastatin is the most widely prescribed statin globally and the one most studied for primary prevention in diverse populations. Doses range from 10 mg to 80 mg daily. At 10 mg, expect a 37% LDL reduction; at 40-80 mg (high-intensity dosing per ACC/AHA definitions), expect 50-51%. The ASCOT-LLA trial (N=10,305 hypertensive patients with average total cholesterol <251 mg/dL) found that atorvastatin 10 mg daily reduced fatal and non-fatal MI by 36% versus placebo (HR 0.64 to 95% CI 0.50-0.83) over a median 3.3 years. [9] Atorvastatin is metabolized by CYP3A4, meaning dose adjustments may be needed with azole antifungals, some HIV antiretrovirals, and clarithromycin.

Rosuvastatin (Crestor)

Rosuvastatin achieves the greatest LDL reduction per milligram of any available statin. At 10 mg it reduces LDL by approximately 45-48%; at 40 mg (maximum approved dose) by approximately 55%. Because it is not significantly metabolized by CYP3A4, it carries a lower drug-drug interaction burden than atorvastatin for patients on complex regimens. The JUPITER data above apply directly to rosuvastatin's primary prevention evidence base. [7] Asian patients may require lower starting doses (5 mg) due to higher plasma concentrations observed in pharmacokinetic studies. [10]

Simvastatin (Zocor)

Simvastatin was among the earliest statins available and has an extensive evidence base in secondary prevention, particularly from the 4S trial. For primary prevention, its use has become more limited since the FDA's 2011 safety communication restricting the 80 mg dose due to an unacceptably high myopathy risk (approximately 0.61% incidence of myopathy at 80 mg vs. 0.04% at 20 mg in the SEARCH trial). [11] Current clinical practice typically caps simvastatin at 40 mg daily for new prescriptions. At 20-40 mg, simvastatin achieves roughly 35-41% LDL reduction. It shares the CYP3A4 interaction profile with atorvastatin, and the drug interaction list is extensive, including amlodipine (cap at 20 mg simvastatin), amiodarone, and diltiazem.

Ezetimibe (Zetia)

Ezetimibe blocks intestinal cholesterol absorption at the Niemann-Pick C1-Like 1 (NPC1L1) transporter, independent of statin mechanism. Used as monotherapy in statin-intolerant patients, it reduces LDL by 18-25%. Added to a statin, it provides an additional 18-25% reduction on top of whatever the statin achieves. The IMPROVE-IT trial (N=18,144 post-ACS patients) showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the primary MACE endpoint by an absolute 2 percentage points over 7 years (32.7% vs. 34.7%, HR 0.936 to 95% CI 0.89-0.99, P<0.016). [12] While IMPROVE-IT was a secondary prevention trial, it provided the first direct evidence that lowering LDL via a non-statin mechanism translates to cardiovascular benefit, supporting the "lower is better" principle in high-risk primary prevention patients who cannot achieve LDL targets on statin alone.

Ezetimibe is generic and inexpensive. It has no significant drug-drug interactions and is generally well tolerated. For primary prevention patients on a moderate-intensity statin who remain above their LDL target (typically <100 mg/dL for 10-year risk 7.5-20%, and <70 mg/dL for risk above 20%), adding ezetimibe before escalating to injectable PCSK9 inhibitors is the standard next step per ACC/AHA guidelines. [8]

How Aspirin and Statins Interact: Can You Take Both?

Taking a statin does not preclude aspirin, and stopping aspirin does not mean abandoning all cardiovascular risk reduction. These are parallel but independent decisions.

For a 55-year-old with a 12% 10-year ASCVD risk and LDL of 155 mg/dL, the evidence supports starting a moderate-intensity statin (atorvastatin 10-20 mg or rosuvastatin 5-10 mg) after a clinician discussion. Whether to add aspirin requires a separate assessment of bleeding risk. If that same patient has a history of peptic ulcer disease, the bleeding risk likely outweighs the incremental platelet benefit that aspirin would add on top of statin therapy.

The European Society of Cardiology 2021 Guidelines on Cardiovascular Disease Prevention take an even more conservative position, stating that antiplatelet therapy (including aspirin) is not recommended for primary prevention in patients without established CVD due to the excess risk of major bleeding. [13] That position aligns closely with the current USPSTF stance.

Bleeding Risk Quantification: What Numbers Should Drive the Conversation

Clinicians often underestimate absolute bleeding risk because relative risk figures dominate the literature. Concrete absolute numbers are more useful in the exam room.

In ASPREE, major hemorrhage rates were 3.8% over 4.7 years with aspirin versus 2.8% with placebo, an absolute difference of 1.0 percentage point. [2] In ARRIVE, GI bleeding was 0.97% versus 0.46% over 5 years. [3] In ASCEND, major bleeding was 4.1% versus 3.2% over 7.4 years. [4] Across all three trials, the absolute bleeding excess runs approximately 0.5 to 1.0 percentage points, which is nearly identical to the absolute cardiovascular benefit in the same populations.

Gastrointestinal bleeding is the most common serious complication. Hemorrhagic stroke is less common but more severe. Patients who use NSAIDs regularly (ibuprofen, naproxen) face compounded bleeding risk if aspirin is added, and this combination should trigger a frank discussion about whether the cardiovascular benefit hypothesis even holds.

A practical decision framework: calculate the patient's 10-year ASCVD risk using the Pooled Cohort Equations. If risk is <10%, aspirin confers no meaningful primary prevention benefit in current evidence. If risk is 10-20% and age is 40-59, quantify bleeding risk (prior GI bleed, NSAID use, anticoagulation, peptic ulcer history, uncontrolled hypertension) and have an individualized discussion. If age is 60 or above, the Grade D USPSTF recommendation applies regardless of risk level; do not initiate. If aspirin is already being taken, whether to stop it requires a separate clinical judgment, because abrupt cessation in patients with borderline risk profiles carries its own rebound platelet activation concerns.

Special Populations: Diabetes, Hypertension, and Older Adults

Diabetes without established CVD: ASCEND is the defining trial. The near-identical absolute benefit and harm mean the decision is genuinely a coin flip for most patients. The American Diabetes Association's Standards of Medical Care in Diabetes 2024 states that aspirin therapy (75-162 mg daily) may be considered for adults with diabetes and intermediate CVD risk (10-year risk 5-10%) after shared decision-making, acknowledging the limited net benefit. [14]

Hypertension: Uncontrolled hypertension above 180/110 mmHg independently raises intracranial hemorrhage risk. Aspirin should not be started in patients with uncontrolled hypertension, and blood pressure control should be optimized before any aspirin conversation takes place.

Adults 70 and older: ASPREE is definitive here. The all-cause mortality signal (HR 1.14 to 95% CI 1.01-1.29) and major hemorrhage excess mean there is no acceptable risk-benefit trade-off for starting aspirin in this age group for primary prevention. [2]

Stopping Aspirin Already in Progress: What Happens

Patients who have been taking daily aspirin for years based on older guidance often ask whether they should stop. The answer is not straightforward.

Observational data suggest a rebound platelet hyper-reactivity in the days following aspirin cessation, though randomized evidence on clinical outcomes after stopping in primary prevention patients is limited. A 2022 analysis of the ASPREE cohort found no significant short-term increase in cardiovascular events after stopping trial medication at study end, which provides some reassurance. [2] Patients who have taken aspirin for more than five years and are now over 60 should discuss stopping with their physician. The decision should account for whether any borderline indications (very high 10-year ASCVD risk, prior TIA without confirmed atherosclerosis) have accumulated over time.

Switching from aspirin-centered prevention to statin-centered prevention is not a downgrade. Starting or optimizing a high-intensity statin in an aspirin-stopping patient represents a more evidence-supported intervention at the same time.

Lifestyle Factors That Outperform Aspirin in Absolute Risk Reduction

No pharmacologic agent for primary prevention replaces lifestyle modification, and the absolute risk reductions from lifestyle changes often exceed those from low-dose aspirin in primary prevention populations.

Smoking cessation alone reduces 10-year ASCVD risk by 30-50% depending on pack-year history and age of cessation. A Mediterranean-style dietary pattern reduced the composite of MI, stroke, and cardiovascular death by 30% (HR 0.70 to 95% CI 0.54-0.92) in the PREDIMED trial (N=7,447), an absolute reduction of approximately 3 percentage points over 4.8 years. [15] Regular aerobic exercise (150 minutes per week of moderate-intensity activity per CDC physical activity guidelines) independently reduces cardiovascular mortality risk by 20-35%. [16] These numbers dwarf the 0.5-1.0 percentage point absolute benefit of aspirin in primary prevention.

Blood pressure control to below 130/80 mmHg in hypertensive patients reduces stroke risk by approximately 35-40% and coronary events by 20-25%, again far exceeding aspirin's primary prevention effect size.

The practical implication: before raising aspirin in a primary prevention consultation, confirm that smoking cessation counseling has been offered, dietary quality has been assessed, physical activity has been quantified, blood pressure is at goal, and statin eligibility has been evaluated.